Stroke prevention with lipid-lowering therapy

References

• Fujii S, Sobel BE. Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor Type 1. Circulation 85(5), 1888–1893 (1992).
   Google Scholar
• Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARa activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99(24), 3125–3131 (1999).
   Google Scholar
• Staels B, Koenig W, Habib A et al Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPARy activators. Nature 393(6687), 790–793 (1998).
   PubMed Web of Science ®Google Scholar
• Seiler C, Suter TM, Hess OM. Exercise- induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. jAm. Coll Camlial 26(7), 1615–1622 (1995).
   Google Scholar
• Borghi C, Veronesi M, Prandin MG, Dormi A, Ambrosioni E. Statins and blood pressure regulation. CUI7: Hypertens. Rep. 3(4), 281–288 (2001).
   Google Scholar
• Kwak B, Mulhaupt F, Myit S, Mach Statins as a newly recognized type of immunomodulator. Nat Med. 6, 1399–1402 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenson TS, Tangnez CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAIVIA 279 (20), 1643–1650 (1998).
   PubMed Web of Science ®Google Scholar
• Vaughan CJ, Dalanty N. Neuroprotective properties of statins in cerebral ischaemia and stroke. Stroke 30,1969–1973 (1999).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Clearfield M et al Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Eng. Med 344,1959–1965 (2001).
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF Effect of aggressive versus conventional lipil lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357(9256), 577–581 (2001).
   PubMed Web of Science ®Google Scholar
• Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann. Epidemial 2(1–2), 23–28 (1992).
   Google Scholar
• ••Gold standard epidemiological study.
   Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16(2), 434–444 (1993).
   Google Scholar
• ••Gold standard epidemiological study.
   Google Scholar
• Emond MJ, Zareba W Prognostic value of cholesterol in women of different ages. J. Women Health (6), 295–307 (1997).
   PubMed Web of Science ®Google Scholar
• Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 346, 1647–1653 (1995).
   PubMed Web of Science ®Google Scholar
• •A combined analysis of cohort trials on cholesterol levels and stroke rate.
   Google Scholar
• Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and 6-year mortality from stroke in 350,977 men screened for the multiple risk factors interventional trial. N Eng. J. Med. 320, 904–910 (1989).
   Google Scholar
• •Longitudinal study of 350,000 men screened for multiple risk factors.
   Google Scholar
• Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol and stroke in eastern Asian. Lancet352, 1801–1807 (1998).
   PubMed Web of Science ®Google Scholar
• •Systematic review of 13 Asian cohorts (125,000 subjects).
   Google Scholar
• Lindenstrom E, Boysen G, Nyobe J. Influence of total cholesterol, high density lipoprotein cholesterol and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BE Med. J. 309,11-15 (1994).
   Google Scholar
• Hachinski V, Graffagnino C, Beaudry M et al. Lipids and stroke: a paradox resolved. Adb. Neural 53(4), 303–308 (1996).
   Web of Science ®Google Scholar
• Tanne D, Koren-Morag N, Graff E, Goldbourt U. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) registry: high triglycerides constitute an independent risk factor. Circulation 104(24), 2892–2897 (2001).
   PubMed Web of Science ®Google Scholar
• Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease and death. The Framingham Study. Adb. Intern. Med. 141(9), 1128–1131 (1981).
   Google Scholar
• Njolstad I, Arnesen E, Lund-Larsen PG. Body height, cardiovascular risk factors and risk of stroke in middle-aged men and women. A 14-year follow-up of the Finnmark Study. Circulation 94(11), 2877–2882 (1996).
   Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Eng J. Med 335(14), 1001–1009 (1996).
   Google Scholar
• •Randomized trial on secondary coronary prevention.
   Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Eng. Med. 339,1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• •Randomized trial on secondary coronary prevention.
   Google Scholar
• Plehn JF, Davis BR, Sacks FM et al Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 99(2), 216–223 (1999).
   PubMed Web of Science ®Google Scholar
• •Randomized trial on secondary coronary prevention.
   Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Eng J. Med. 339(19), 1349–1357 (1998).
   Google Scholar
• •Randomized trial on secondary coronary prevention.
   Google Scholar
• White HD, Simes RJ, Anderson NE et al. Pravastatin therapy and the risk of stroke. N. Eng: Med 343(5), 317–326 (2000).
   PubMed Web of Science ®Google Scholar
• LIPID (Long-term Intervention with Pravastatin in Ischaemic Disease) Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359(9315), 1379–1387 (2002).
   Google Scholar
• Shepherd J, Cobbe SM, Ford I et al Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Eng. J. Med 333(20), 1301–1307 (1995).
   Google Scholar
• •Randomized trial on primary coronary prevention.
   Google Scholar
• ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) . JAIVIA 288 (23), 2998–3007 (2002).
   Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al Prospective study of pravastatin in the elderly at risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360(9346), 1623–1630 (2002).
   PubMed Web of Science ®Google Scholar
• ••Randomized trial on primary andsecondary prevention of cardiac and brain ischemic complications.
   Google Scholar
• Wierzbicki AS, Mikhailidis DP, Reynolds TM. More on PROSPER. Lancet 361(9363), 1135–1136 (2003).
   PubMed Web of Science ®Google Scholar
• Byington RP Davis BR, Plehn JF et al Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 103(3), 387–392 (2001).
   PubMed Web of Science ®Google Scholar
• •Summary of pravastatin trials.
   Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) . Lancet 344 (8934), 1383–1389 (1994).
   Google Scholar
• ••Randomized trial on secondary coronaryprevention and primary stroke prevention in high-risk patients.
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326), 7–22 (2002).
   Google Scholar
• Athyros VG, Papageorgiou AA, Mercouris BR et al Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. CUI7: Merl Res. Opin. 18(4), 220–228 (2002).
   Google Scholar
• The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 102,21–27 (2000).
   PubMed Web of Science ®Google Scholar
• Rubins FIB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Eng. I Merl 341(6), 410–418 (1999).
   Google Scholar
• Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann. Intern. Merl 119(2), 136–145 (1993).
   Google Scholar
• •First systematic review of lipid lowering strategies.
   Google Scholar
• Di Mascio R, Marchioli R, Tognoni G. Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials. Cerebrovasc. Dis. 10(2), 85–92 (2000).
   Google Scholar
• •A systematic review of lipid lowering strategies.
   Google Scholar
• Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez F Lechat P Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch. Intern Merl 163(6), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• •Most recent systematic review of lipid-lowering strategies.
   Google Scholar
• Manktelow B, Gillies C, Potter JE Interventions in the management of serum lipids for preventing stroke recurrence. In: The Cochrane Library Issue Four John Wiley & Sons Ltd, Chichester, UK (2003).
   Google Scholar
• •Cochrane systematic review of lipid-lowering strategies in cardiovascular prevention.
   Google Scholar
• Amarenco P, Bogousslavsky J, Callahan AS et al. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cenbrovasc. Dis. 16(4), 389–395 (2003).
   PubMed Web of Science ®Google Scholar
• Goldstein L, Amarenco P, Bogousslavsky J et al. Statins for secondary stroke prevention in patients without known coronary heart disease: the jury is still out. Cembrovasc. Dis. (2004) (In Press).
   Google Scholar
• Aminbakhsh A, Mancini GB. Carotid intima-media thickness measurements: what defines an abnormality? A systematic review. Clin. Invest. Merl 22(4), 149–157 (1999).
   Google Scholar
• Hacke W, Kaste M, Bogousslavsky J et al. European Stroke Initiative Executive Committee and the EUSI Writing Committee. European Stroke Initiative Recommendations for Stroke Management —update 2003. Cerebrovasc. Dis. 16(4), 311–337 (2003).
   Google Scholar
• ••European recommendations forstroke treatment.
   Google Scholar